OUR MISSION

We are committed to providing patients living with chronic diseases an alternative to injectable and other inhaled formulation technologies, ultimately improving their treatment efficacy and treatment experience.

OUR APPROACH

Our product development approach combines novel formulations of existing drugs with our inhalation technology for the treatment of rare and severe chronic diseases with high unmet medical need.

MANAGEMENT TEAM

Our management team brings together formulation, device development, clinical and commercial expertise.

BOARD OF DIRECTORS

Anne Whitaker, Chief Executive Officer and Director

John Patton, PhD, Director and Founder

Steve Thornton, Chairman, Chair of Compensation Committee

Adam Stern, Director

Benjamin Wolin, Director, Chair of Nomination and Governance Committee

Bill Welch, Director

Kenneth B. Lee, Jr. Director, Chair of Audit Committee

CAREERS

Join us in our effort to redefine the treatment of chronic diseases with inhaled therapies.